HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peritoneal Fibrosis

Disorder characterized by a wide range of structural changes in PERITONEUM, resulting from fibrogenic or inflammatory processes. Peritoneal fibrosis is a common complication in patients receiving PERITONEAL DIALYSIS and contributes to its gradual decrease in efficiency.
Also Known As:
Encapsulating Peritoneal Scleroses; Fibroses, Peritoneal; Fibrosing Syndrome, Peritoneal; Fibrosing Syndromes, Peritoneal; Fibrosis, Peritoneal; Peritoneal Fibroses; Peritoneal Fibrosing Syndromes; Peritoneal Scleroses; Peritoneal Scleroses, Encapsulating; Peritoneal Sclerosis, Encapsulating; Scleroses, Encapsulating Peritoneal; Scleroses, Peritoneal; Sclerosis, Encapsulating Peritoneal; Sclerosis, Peritoneal; Syndrome, Peritoneal Fibrosing; Syndromes, Peritoneal Fibrosing; Encapsulating Peritoneal Sclerosis; Peritoneal Fibrosing Syndrome; Peritoneal Sclerosis
Networked: 1052 relevant articles (79 outcomes, 125 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Peritoneal Fibrosis
2. Fibrosis (Cirrhosis)
3. Inflammation (Inflammations)
4. Peritonitis
5. Dysbiosis

Experts

1. Kawanishi, Hideki: 25 articles (01/2021 - 01/2002)
2. Krediet, Raymond T: 24 articles (01/2022 - 05/2004)
3. Koji, Takehiko: 18 articles (03/2022 - 01/2003)
4. Nakayama, Masaaki: 18 articles (10/2020 - 01/2002)
5. Nishino, Tomoya: 17 articles (03/2022 - 09/2003)
6. Kohno, Shigeru: 17 articles (01/2019 - 01/2003)
7. Obata, Yoko: 16 articles (03/2022 - 11/2006)
8. Struijk, Dirk G: 16 articles (01/2019 - 01/2007)
9. Hamada, Chieko: 15 articles (01/2021 - 05/2004)
10. Margetts, Peter J: 15 articles (01/2020 - 10/2001)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Peritoneal Fibrosis:
1. Glucose (Dextrose)FDA LinkGeneric
2. chlorhexidine gluconate (Dyna-Hex)FDA LinkGeneric
3. TamoxifenFDA LinkGeneric
4. CollagenIBA
5. VimentinIBA
01/01/2020 - "The results from the in vivo experiments showed that OA-NO2 notably relieved peritoneal fibrosis by decreasing the thickness of the peritoneum; it also inhibited expression of transforming growth factor-β1, α-smooth muscle actin, N-cadherin, and vimentin and enhanced expression of E-cadherin in the peritoneum. "
01/01/2022 - "In murine models of peritoneal dialysis, daily Sal A treatment substantially improved the peritoneal dialysis fluid (PDF) elicited peritoneal fibrosis, marked by thickening of the submesothelial compact zone, accumulation of extracellular matrix and increased expression of vimentin and PAI-1, concomitant with attenuation of GSK3β hyperactivity. "
01/01/2023 - "APC potently inhibited CG-induced peritoneal fibrosis and downregulated the expression of proinflammatory cytokines, collagen deposition, Smad3 phosphorylation, and markers of mesothelial-to-mesenchymal transition (α-smooth muscle actin, vimentin, and N-cadherin). "
08/01/2023 - "Compared with the control group, PDF with different sugar contents could induce peritoneal fibrosis in rats, and the degree of fibrosis was gradually aggravated with the increase of sugar content, which was manifested as peritoneal thickening, increased collagen fiber deposition, decreased peritoneal ultrafiltration volume, down-regulated expressions of E-cadherin and MMP-9 in peritoneal tissue, and up-regulated expressions of α-SMA, Vimentin, TIMP-1 and TGF-β1, and the pathological changes and ECM accumulation in peritoneal tissues were more serious in 4.25% PDF model group. "
08/01/2023 - "After the intervention of modified Shenling Baizhu San, compared with the corresponding PDF model groups, the peritoneal fibrosis of rats was improved to varying degrees, and the effect of the 4.25% PDF+traditional Chinese medicine intervention group was more significant, the parietal peritoneum was significantly thinner (μm: 101.86±16.01 vs. 140.65±10.13, P < 0.05), collagen fiber deposition was significantly reduced, peritoneal ultrafiltration volume was significantly increased (mL: -0.01±3.45 vs. -3.53±1.84, P < 0.05), the expressions of E-cadherin and MMP-9 in peritoneal tissues were significantly up-regulated [E-cadherin protein (E-cadherin/β-actin): 0.84±0.08 vs. 0.28±0.05, MMP-9 (A value): 0.60±0.15 vs. 0.37±0.01, both P < 0.05], and the expressions of α-SMA, Vimentin, TIMP-1 and TGF-β1 were significantly down-regulated [α-SMA protein (α-SMA/β-actin): 0.36±0.08 vs. 1.05±0.09, Vimentin protein (Vimentin/β-actin): 0.53±0.07 vs. 1.19±0.04, TIMP-1 (A value): 0.49±0.06 vs. 0.87±0.02, TGF-β1 (A value): 0.67±0.04 vs. 0.89±0.10, all P < 0.05]. "
6. Transforming Growth Factors (Transforming Growth Factor)IBA
7. Biomarkers (Surrogate Marker)IBA
8. Proteins (Proteins, Gene)FDA Link
9. Pyruvaldehyde (Methylglyoxal)IBA
10. Plasminogen Activator Inhibitor 1IBA

Therapies and Procedures

1. Peritoneal Dialysis
2. Therapeutics
3. Continuous Ambulatory Peritoneal Dialysis (CAPD)
4. Microbubbles
5. Oral Administration